Neoadjuvant cisplatin,methotrexate,and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial

The Lancet

Volumn 354, Issue 9178, 1999, Pages 533-540

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; FOLINIC ACID; METHOTREXATE; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYSTECTOMY; CYSTOVAGINAL FISTULA; DIARRHEA; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSURIA; EXTERNAL BEAM RADIOTHERAPY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; LOCAL THERAPY; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; METASTASIS FREE SURVIVAL; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE INVASIVE BLADDER CANCER; NAUSEA AND VOMITING; NEPHROTOXICITY; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; RADIATION INJURY; RADICAL RESECTION; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIAL; SURGICAL INFECTION; SURGICAL MORTALITY; SURVIVAL RATE; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT REFUSAL; TREATMENT RESPONSE; WOUND DEHISCENCE;

EID: 85014013850     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)02292-8     Document Type: Article

References (25)

1. 1 Sternberg, CN, Yagoda, A, Scher, HI, et al. Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 64 (1989), 2448–2458.
2. 2 Harker, WG, Meyers, FJ, Freiha, FS, et al. Cisplatin, methotrexate and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract—a Northern California Oncology Group Study. J Clin Oncol 3 (1985), 1463–1470.
3. 3 Saxman, SB, Propert, KJ, Einhorn, LH, et al. Long-term follow-up of phase II intergroup study of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15 (1997), 2564–2569.
4. 4 Mead, GM, Russell, M, Clark, P, et al. A randomised trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors—a Medical Research Council study. Br J Cancer 78 (1998), 1067–1075.
5. 5 Scher, HI, Yagoda, A, Herr, HW, et al. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin); effect on the primary bladder lesion. J Urol 139 (1988), 470–474.
6. 6 Scher, HI, Systemic chemotherapy in regionally advanced bladder cancer: theoretical considerations and results. Urol Clin North Am 19 (1992), 747–759.
7. 7 Splinter, TAW, Denis, L, Scher, HI, Schroder, FH, Dalesio, O, Neoadjuvant chemotherapy for locally advanced bladder cancer. Murphy, GP, Khoury, S, (eds.) Therapeutic progress in urological cancers., 1989, Alan R Liss, New York, 525–531.
8. 8 Hall, RR, Roberts, JT, Neoadjuvant chemotherapy, a way to conserve the bladder?. Eur J Can, 27(suppl 2), 1991, S29 abstr 144.
9. 9 Coppin, C, Gospodarowicz, M, Dixon, P, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or radical radiation. Proc ASCO, 11, 1992, 198 abstr 607.
10. 10 Wallace, DMA, Raghavan, D, Kelly, KA, et al. Neo-adjuvant (preemptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 67 (1991), 608–615.
11. 11 Martinez-Pineiro, JA, Gonzalez Martin, M, Arocena, F, et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomised phase III study. J Urol 153 (1995), 964–973.
12. 12 Rhintala, E, Hannisdal, E, Fossa, SD, Hellsten, S, Sander, S, Neoadjuvant chemotherapy in bladder cancer: a randomised study—Nordic Cystectomy Trial I. Scand J Urol Nephrol 27 (1993), 355–362.
13. 13 Ghersi, D, Stewart, LA, Parmar, MKB, et al. Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Br J Urol 75 (1995), 206–213.
14. 14 Skinner, D, Daniels, JR, Russell, CA, et al. Adjuvant chemotherapy following cystectomy benefits patients with deeply invasive bladder cancer. Semin Urol 8 (1990), 279–284.
15. 15 Stockle, M, Meyenburg, W, Wellek, S, et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 153 (1995), 47–52.
16. 16 Freiha, F, Reese, J, Torti, FM, Scher, HI, A randomised trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 155 (1996), 495–500.
17. 17 UICC (Union International contre le Cancer). TNM classification of malignant tumors, 1987, International Union against Cancer, Geneva.
18. 18 Cockcroft, DW, Gault, MH, Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976), 31–41.
19. 19 Parmar, MKB, Machin, D, Survival analysis: a practical approach, 1995, John Wiley, Chichester.
20. 20 Browman, GP, Goodyear, MDE, Levine, MN, Russell, R, Archibald, SD, Young, JEM, Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: a randomised placebo-controlled clinical trial. J Clin Oncol 8 (1990), 203–208.
21. 21 Roberts, JT, Bladder preservation in muscle invasive bladder cancer. Hall, RR, (eds.) The clinical management of bladder cancer, 1998, Kluwer Academic and Lippincott Raven, London.
22. 22 Shearer, RJ, Chilvers, CED, Bloom, HJG, Bliss, JM, Horwich, A, Babiker, A, Adjuvant chemotherapy in T3 carcinoma of the bladder: a prospective trial—preliminary report. Br J Urol 62 (1988), 558–564.
23. 23 Malmstrom, PU, Rintala, E, Wahlqvist, R, et al. Five year follow up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial. J Urol 155 (1996), 1903–1906.
24. 24 Shipley, WU, Winter, KA, Kaufman, DS, et al. An RTOG phase III trial (#89-03) of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy. Proc ASCO, 17, 1998 abstr 1197.
25. 25 Abol-Enein, H, El-Makresh, M, El-Baz, M, et al. Neoadjuvant chemotherapy in the treatment of invasive transitional bladder cancer: a controlled prospective randomised study. Br J Urol, 79(suppl 3), 1997, 43 abstr 174.